Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation. [electronic resource]
Producer: 20150626Description: 362-7 p. digitalISSN:- 1872-7972
- Administration, Intranasal
- Alzheimer Disease -- drug therapy
- Amyloid -- metabolism
- Amyloid beta-Protein Precursor -- genetics
- Animals
- Deferoxamine -- pharmacology
- Glycogen Synthase Kinase 3 -- metabolism
- Glycogen Synthase Kinase 3 beta
- Iron Chelating Agents -- pharmacology
- Male
- Memory Disorders -- drug therapy
- Memory, Long-Term -- drug effects
- Memory, Short-Term -- drug effects
- Mice, Transgenic
- Oxidative Stress
- Presenilin-1 -- genetics
- Signal Transduction
- beta Catenin
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.